Newsletters
Idil Bilgen’s recent win as Miss Türkiye 2024 sparked widespread controversy across social media and among public figures.
While many celebrated her intelligence and medical background, others accused her of gaining the title through favoritism.
Bilgen, a doctor who has recently started her new position in Bingol, Türkiye, faces criticism from those who question both her appearance and the legitimacy of her victory. This debate has raised discussions about beauty standards and fairness in the Miss Türkiye competition.
Idil Bilgen, 24, is a graduate of Koc University’s Faculty of Medicine and currently works as a doctor at a health center in Yayladere, Bingol. She earned the Miss Türkiye 2024 crown in a competition featuring 20 finalists, stating, “Before being named Miss Türkiye, I was already a doctor. I’m honored to carry both titles at the same time.”
Bilgen’s victory quickly became a hot topic on social media. Users questioned her looks and implied that her father’s position as Türkiye’s ambassador to Ukraine influenced the results.
Comments such as, “Did she win through connections?” and “We didn’t say you couldn’t be a doctor, we just said you aren’t beautiful,” circulated widely.
In response to the criticism, Bilgen said, “I don’t care about these comments. I am a modern Turkish woman, and I will represent Türkiye with pride.”
Public figures also weighed in on the controversy. While some backed Bilgen, others were critical:
Bilgen’s win has reignited conversations about evolving beauty standards in Türkiye. While some see her as a symbol of modern beauty, others remain attached to traditional views. Many critics speculated whether the competition was fair, or if Bilgen’s family connections influenced the outcome.
In her defense, Bilgen reiterated, “Miss World crowns educated women. This isn’t about just being physically attractive.”
Bilgen will represent Türkiye at the upcoming Miss World pageant. While preparing for the global stage, she remains dedicated to her medical career, particularly her focus on cancer research.
2 min read
